Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker, and basic scientist. From 2013 until October 2019, Sam was a Partner at Apple Tree Partners (ATP), a New York-based life sciences venture capital firm with $2.5 billion under management. At ATP Sam co-led the therapeutics investing practice and focused principally on the formation and growth of new biotechnology companies. During his tenure Sam served as a director of ATP portfolio companies Syntimmune, Elstar Therapeutics, Limelight Bio and Chinook Therapeutics and he continues to serve as a director of Stoke Therapeutics (NASDAQ: STOK). Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.